文献速递冠心病心力衰竭与心肌病

低剂量利伐沙班预防前壁心梗后左室血栓的随机临床试验

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

APERITIF多中心开放标签盲终点随机试验纳入560例前壁STEMI患者,比较DAPT联合低剂量利伐沙班与单用DAPT对1个月左室血栓的影响。

要点

  • 前壁STEMI患者DAPT加用利伐沙班2.5mg每日两次未显著减少1个月左室血栓。
  • 联合利伐沙班组轻微出血(BARC 1型)发生率高于单用DAPT组。
  • 主要出血事件(BARC≥2型)两组相当,但研究把握度有限需谨慎解读。

核心结论

  • 在前壁STEMI患者中,DAPT联合低剂量利伐沙班未显著降低1个月左室血栓发生率,但增加轻微出血。

研究设计与样本

  • 多中心、开放标签、盲终点随机临床试验,嵌套于FRENCHIE注册研究,在法国29个中心进行。
  • 2021年10月至2023年1月纳入前壁STEMI患者,随机分为DAPT联合利伐沙班2.5mg每日两次组(n=283)或单用DAPT组(n=277)。

主要发现

  • 两组左室血栓最大直径及主要不良心血管事件发生率无差异。
  • 主要出血事件(BARC≥2型):利伐沙班组4例(1.5%),单用DAPT组2例(0.7%),差异0.7%(95%CI -1.3%至3.1%)。
  • 轻微出血事件(BARC 1型):利伐沙班组45例(16.4%),单用DAPT组20例(7.2%),差异9.3%(95%CI 3.6%-14.8%)。

临床怎么用

  • 对于前壁STEMI患者,在DAPT基础上加用低剂量利伐沙班预防左室血栓的证据尚不充分,需权衡轻微出血风险。

局限性

  • 研究把握度有限,不能排除 modest 效应,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anterior acute myocardial infarction is associated with increased risk of left ventricular (LV) thrombus. The benefit and risk of adding an oral anticoagulant to dual antiplatelet therapy (DAPT) in preventing LV thrombus remain uncertain. OBJECTIVE: To determine whether the addition of low-dose rivaroxaban to DAPT reduces the incidence of LV thrombus at 1 month in patients with anterior ST-segment elevation myocardial infarction (STEMI). DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded-end point randomized clinical trial was performed in 29 centers in France. The trial was nested in the ongoing FRENCHIE (French Cohort of Myocardial Infarction Evaluation) registry. Between October 2021 and January 2023, patients with anterior STEMI were enrolled. The last date of participant follow-up was in March 2023. Data analysis was performed from September 2024 to July 2025. INTERVENTIONS: Patients were randomized to receive either DAPT plus rivaroxaban, 2.5 mg, twice daily for 4 weeks (n = 283) or DAPT alone (aspirin ≤100 mg per day and either clopidogrel, 75 mg per day, or ticagrelor, 90 mg twice a day [n = 277]), as soon as possible following completion of the initial percutaneous coronary intervention or angiography procedure. MAIN OUTCOMES AND MEASURES: The primary end point was presence of LV thrombus on contrast-enhanced cardiac magnetic resonance imaging at 1 month. RESULTS: Among 560 patients with anterior STEMI enrolled (mean [SD] age, 61.1 [11.6] years; 121 female patients [21.6%]), LV thrombus was detected in 38 patients (13.7%) receiving rivaroxaban and 47 patients (16.6%) with DAPT alone (difference, -2.9%; 95% CI, -8.9% to 3.2%; P = .34). No difference was observed between the 2 groups regarding the largest diameter of LV thrombus or the incidence of major adverse cardiovascular events. The incidence of major bleeding events (Bleeding Academic Research Consortium [BARC] ≥type 2) was also comparable (4 [1.5%] with DAPT plus rivaroxaban vs 2 [0.7%] with DAPT alone; difference, 0.7%; 95% CI, -1.3% to 3.1%), whereas minor bleeding events (BARC type 1) occurred more frequently in the DAPT plus rivaroxaban group (45 [16.4%] vs 20 [7.2%]; difference, 9.3%; 95% CI, 3.6%-14.8%). CONCLUSIONS AND RELEVANCE: In this multicenter randomized clinical trial among patients with anterior STEMI, the addition of low-dose rivaroxaban to DAPT did not demonstrate a statistically significant reduction in LV thrombus formation at 1 month but did increase minor bleeding. Given the limited power of the study, these findings should be interpreted with caution, as a modest effect cannot be excluded. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05077683.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Puymirat E, Soulat G, Lattuca B, et al. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41739450. doi:10.1001/jamacardio.2026.0026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。